Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant

Condition

Blood and Immune System

Cancer

1 July 2026

-

Published on 01 Jul 2026
Last Updated on 01 Jul 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Glofitamab 2.5 mg and 10 mg concentrate for solution for infusion, for use in combination with gemcitabine and oxaliplatin, for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant.

Funding status

Glofitamab 2.5 mg and 10 mg concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.

Clinical indication, subsidy class and MediShield Life claims eligibility for glofitamab are provided in the Annex.

Guidance_Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant (1 Jul 2026) [PDF, 297.83 KB]

Back to top